TruAlt Bioenergy RPT approval for ₹2,500 crore FY27

Shareholders clear related party transaction limit

TruAlt Bioenergy Limited has secured shareholder approval for material related party transactions (RPTs) with Nirani Sugars Limited for the financial year 2026-27. The resolution authorises an aggregate transaction value of up to ₹2,500 crore. The approval was granted through a remote e-voting process, with the company disclosing that 99.98% of the votes polled were in favour.

The mandate allows TruAlt Bioenergy to continue its existing contracts and also enter into new arrangements with the related party. The company stated that the transactions cover the purchase and sale of goods and materials. Such approvals are a key compliance requirement when transaction values cross prescribed thresholds.

How the vote played out

The remote e-voting process concluded on July 9, 2026. As per the disclosed voting outcome, a total of 62,51,964 votes were polled. Of these, 62,50,561 shares voted in favour of the resolution, while 1,403 shares voted against it.

The near-unanimous result indicates that shareholders broadly supported management’s proposal to set a higher transaction cap for FY2026-27. The vote also provides operating flexibility for routine procurement and sales flows that can arise within group-linked supply chains.

What the approval enables for FY2026-27

The company’s disclosure indicates that the RPT approval is meant to support ongoing and new arrangements for the purchase and sale of goods and materials with Nirani Sugars. In practice, shareholder authorisation at the stated limit can help avoid repeated approvals during the year for similar categories of dealings, provided transactions remain within the approved ceiling.

For investors, the key point is that the approval is for an upper cap of ₹2,500 crore for FY2026-27. It does not, by itself, indicate that the full amount will necessarily be utilised. The resolution primarily addresses governance requirements for material transactions with a related party.

Financial context: FY26 profit and revenue decline

The RPT approval comes at a time when the company has reported weaker consolidated profitability. TruAlt Bioenergy reported a consolidated net profit of ₹96.8698 crore for FY26, down from ₹146.6385 crore in the previous year.

Revenue from operations also declined, falling to ₹1,727.5066 crore. The figures provide context for shareholders assessing large transaction limits, since related-party purchases and sales can materially influence operating flows, working capital movements, and reported revenues.

Key facts at a glance

Strategic collaboration: Sumitomo and TruAlt Gas plans

Separately, Sumitomo Corporation announced that it agreed on November 11, 2025 to acquire a portion of the shares of TruAlt Gas Private Limited (TGPL), a subsidiary of TruAlt Bioenergy, and enter into a strategic collaboration with TruAlt. Following the acquisition, TGPL plans to change its name to TruAlt Sumi Gas Private Limited (TSGPL).

TSGPL aims to construct 16 compressed biomethane gas (CBG) production facilities across India over the next three years and commence operations sequentially from 2026. The total daily production capacity of these 16 facilities is expected to reach about 320 tons, which Sumitomo’s note equated to daily gas consumption of around 800,000 households in India. Raw materials are expected to include sugarcane and ethanol residue at TruAlt and other suppliers, with CBG primarily intended to be sold as automobile fuel to major city gas distributors in India.

The collaboration also includes plans to work on expanding bioethanol production and producing sustainable aviation fuel (SAF) derived from bioethanol. Sumitomo’s note added that construction is planned to start with four CBG production facilities in Karnataka and Maharashtra while strategies and feasibility studies are carried out for broader expansion.

Regulatory and capacity milestones referenced in disclosures

The Ministry of Environment, Forest and Climate Change accorded environmental clearance for the establishment of a 500 KLPD multi-feed distillery along with a 10 MW co-generation power plant at Village Jalageri, Tehsil Badami, District Bagalkot, Karnataka by TruAlt Bioenergy Ltd (Unit-IV), subject to compliance conditions.

In operational updates cited in the provided material, the company noted it had established Unit 5 with an installed capacity of 200 KLPD as of March 31, 2025, but it did not form part of operational capacity because the Consent to Operate (CTO) was awaited. The same material also referenced one CBG unit as operational with a capacity of 10.2 TPD.

Funding and project pipeline signals

The provided information also references a June 18 update stating that TruAlt Bioenergy secured ₹150 crore approval under PM JI-VAN for a 10 crore-litre SAF project in Bagalkot. In addition, IPO-related details referenced in the material include a price band of ₹472-₹496 and an issue window of September 25, 2025 to September 29, 2025, with the equity shares proposed to be listed on BSE and NSE.

Why the RPT decision matters for investors

Large RPT limits are a governance-sensitive topic because they can be material to revenue recognition, input sourcing, and pricing discipline, especially when transactions are with entities that share promoter or management links. In TruAlt Bioenergy’s case, the resolution explicitly covers purchase and sale of goods and materials, and the cap of ₹2,500 crore sets a high ceiling for FY2026-27.

The voting outcome shows that shareholders overwhelmingly supported the resolution. At the same time, the FY26 decline in consolidated net profit and revenue from operations provides an important backdrop for tracking how operational performance evolves while the company continues group-linked commercial arrangements.

Conclusion

TruAlt Bioenergy’s shareholders have approved an aggregate RPT limit of up to ₹2,500 crore with Nirani Sugars for FY2026-27, with 99.98% votes in favour after the July 9, 2026 e-voting process. Investors will watch how these approved purchase and sale arrangements play out alongside the company’s reported FY26 profit decline and its broader biofuels and CBG expansion initiatives scheduled to begin operations from 2026.